Background-Little is known about the clinical features, procedural risks, or survival of patients receiving replacement versus new implantable cardioverter-defibrillators (ICDs). Methods and Results-Entries in the National Cardiovascular Data Registry (NCDR) ICD Registry from 2005 through 2010 were eligible for inclusion (n=463 978). Baseline demographic data, clinical information, and procedural variables were compared between patients receiving new (n=359 993; 77.6%) and replacement (n=103 985; 22.4%) ICDs and entered into a propensity match model to determine adjusted survival rates. Patients receiving replacement ICDs were older (70.7 versus 67.5 years of age) and more likely to have atrial fibrillation (41.8% versus 31.4%; P<0.001) and ventricular tachycardia (60.5% versus 33.9%; P<0.001) compared with patients receiving new ICDs. Median battery life was only 4.6 years (25%-75% interquartile range, 3.7-5.8) for all replaced devices, 5.8 (25%-75% interquartile range, 4.2-7.5) for single-chamber, 5.1 (25%-75% interquartile range, 4.1-6.1) for dual-chamber, and 3.9 (25%-75% interquartile range, 3.2-4.6) years for biventricular devices. Patients receiving replacement ICDs had lower rates of index admission complications (0.9% versus 3.2%; P<0.001) but greater risk for death compared receiving patients receiving new ICDs in unadjusted analysis (hazard ratio, 1.18; 95% confidence interval, 1.16-1.20; P<0.0001) and after propensity-score matching (hazard ratio, 1.28; 95% confidence interval, 1.25-1.30; P<0.0001). Conclusions-Patients receiving replacement ICDs are older and at greater risk for death compared with those receiving initial ICD implants. The battery life of initial ICDs is shorter than previously reported. (Circ Cardiovasc Qual Outcomes. 2013;06:488-497.)
A pproximately one quarter or more of all implantable cardioverter-defibrillator (ICD) implantations are replacements of existing devices, accounting for 30 000 ICD replacements annually in the United States alone. 1 Yet little is known about the risks and benefits of ICD replacement because these have been largely excluded from clinical trials and the focus of few observational studies. In the years since initial ICD placements, patients may have acquired additional comorbidities or experienced progression of their underlying heart disease, both of which may affect the impact of ICD therapy on clinical outcomes. The paucity of data describing the characteristics and outcomes of patients receiving ICD replacements is a barrier to risk stratification and prognostication, and it explains, in part, the lack of clear indications for replacement in practice guidelines.
Previous risk models for procedural complications have included ICD replacements but provided only limited comparisons with patients receiving initial implants and no assessment of long-term outcomes. [2] [3] [4] Guidelines for ICD implantation do not recommend device therapy for patients with life expectancies of <1 year, 5 but prospectively identifying these patients is difficult. Scoring systems have modeled survival after ICD implantation but only focused on initial implantation. [6] [7] [8] [9] [10] Thus, improved decision making for this common clinical scenario requires better information about outcomes. 11 The goals of this study were to describe and compare patients undergoing replacement and new ICD implantation with regard to (1) characteristics at the time of implantation, (2) risk and distribution of index admission complications, and (3) survival. We hypothesized that patients receiving replacement ICDs would be older, have more accumulated comorbidities, and have poorer survival after their implantation procedures as compared with patients receiving initial ICD implants.
Methods

Data Source
This study analyzed data from the National Cardiovascular Data Registry (NCDR) ICD Registry. This registry was created in 2005 after the Centers for Medicare and Medicaid Services (CMS) national coverage decision for primary prevention ICD implantation. The initial goal was to create a prospective, observational database that would include all Medicare beneficiaries receiving ICDs for primary prevention of sudden cardiac death. Although hospitals are not required to submit data for non-Medicare patients, >75% of the 1489 hospitals participating in the registry have entered data on all ICD implantations regardless of indication or insurance, and it is estimated that 90% of all ICD implants in the United States are captured by this data set, with >10 000 cases entered monthly. 1 All data entry was performed using the ICD Registry Data Collection From v1.08. 12 Participating sites receive formal training on data collection and entry by the NCDR. After submission, data are evaluated for quality and returned to sites if incomplete. Data from the ICD Registry have been used to address key clinical research questions in previous studies. 13, 14 
Study Population
All patients receiving replacement or new ICDs between January 1, 2005, and March 30, 2010, were eligible for inclusion ( Figure 1 ). Patients missing social security numbers and those entered twice into the database (for initial and then replacement implantation) were excluded. Because the primary focus of this study was comparing initial implantation with routine replacement, subjects who did not have end of expected battery life as 1 of the reasons for replacement were also excluded.
Variables
The ICD Registry collects over 130 standardized data elements describing demographic, clinical, and procedural information for each patient receiving an ICD implant. Patient files are linked to the Social Security Death Index to determine patient vital status, which was available up to October 1, 2011. For this report, variables were selected a priori from the ICD Registry that were felt to be necessary to describe and examine the characteristics and outcomes of patients receiving replacement ICD devices based on American College of Cardiology/American Heart Association guidelines for device-based therapy 5 as well as published literature on ICD outcomes (Table 1) . 6, 8 Demographic variables included age, sex, and race (white versus other). Clinical information included data from clinical history and diagnostic studies. History of the following cardiac conditions was collected: any ischemic heart disease, myocardial infarction, coronary artery bypass grafting, congestive heart failure, nonischemic dilated cardiomyopathy (never, past 3 months, past 3-9 months, >9 months), atrial fibrillation, ventricular tachycardia (any), and abnormal sinus node function. Functional status was rated using the New York Heart Association (NYHA) levels I to IV. Finally, the following comorbid conditions were ascertained: cerebrovascular disease, chronic lung disease, diabetes mellitus, hypertension, and renal failure or dialysis.
The most recent diagnostic findings included the left ventricular (LV) ejection fraction (%), QRS duration (ms), atrioventricular conduction problem (none, left bundle-branch block, right bundlebranch block, paced, or other), serum creatinine (mg/dL), serum sodium (mEq/L), and systolic blood pressure (mm Hg). Use of the following cardiac medications at time of discharge was recorded: angiotensin-converting enzyme-inhibitor, angiotensin receptor blocker, amiodarone, aspirin, β-blocker, coumadin, digoxin, and a diuretic.
Procedure characteristics captured in the ICD Registry included identification of new versus replacement ICD procedure. If the device was a replacement, the time elapsed since previous device implant was recorded and whether the procedure also included upgrade to a dual-chamber or biventricular system were identified. The reason for hospitalization during which the device was placed was categorized as follows: ICD placement, congestive heart failure, cardiac but not for congestive heart failure, and noncardiac. Type of device (single chamber, dual chamber, or biventricular) and whether the device was for primary or secondary prevention were also ascertained. (In the ICD Registry, primary prevention indicates that the patient is at risk for but has not yet had an episode of sustained ventricular tachycardia, ventricular fibrillation, or resuscitated cardiac arrest. At the time of ICD replacement, a patient whose device was originally placed for primary prevention but subsequently experienced any of these events would be coded as secondary prevention.) Index admission complications (date of implant through hospital discharge) included: cardiac arrest, drug reaction, cardiac perforation, coronary venous dissection, lead dislodgment, hemothorax or pneumothorax, transient ischemic attack or stroke, myocardial infarction, pericardial tamponade, and infection related to the device. Missing data were present <0.3% of the time for all data elements, and only complete case analysis was used for the propensity-score matching.
Statistical Analysis
All baseline demographic data, clinical information, and procedural variables were described using frequencies for categorical variables and means/medians with SDs/interquartile ranges (IQRs) for continuous variables. Given the size of the population, the comparison of patient and procedural
WHAT IS KNOWN
• Approximately one quarter or more of all implantable cardioverter-defibrillator (ICD) implantations are replacements of existing devices, accounting for 30 000 ICD replacements annually in the United States alone. • Existing outcomes data provide only limited comparisons between patients receiving initial versus replacement implants and no assessment of longterm outcomes including survival. characteristics between subjects who received replacement and initial ICDs were described using percent standardized mean differences (SMDs). An absolute value of ≥10 was considered a meaningful difference. 15 Among subjects who received replacement ICDs, the time (years) from original ICD insertion was calculated and presented overall and stratified by initial device type (single chamber, dual chamber, and biventricular).
WHAT THE STUDY ADDS
Unadjusted survival analysis compared the survival after device placement between subjects who received replacement ICDs and those who received new ICDs using the Kaplan-Meier method and the log-rank test. Median survival was calculated for each group. Hazard ratios (HRs) and 95% confidence intervals were generated from these analyses.
To further evaluate the influence of patient characteristics on survival, propensity-score methods were used. Although not intended (Continued )
to model randomization between having received a replacement versus new ICDs, the propensity-score approach was selected as an alternative method to adjust for potential differences between these groups to minimize parametric assumptions about the relationship between covariates and outcomes while balancing treatment groups on all measured covariates. A propensity score for each patient was generated using a logistic regression model predicting replacement (versus new) ICDs based on the demographic, clinical, and procedural characteristics presented in Table 2 . We then sought to match patients with replacement and initial device insertions by performing a 1:1 nearest neighbor match with a caliper width of 0.2 of the SD of the logit of the propensity score. 16 Absolute SMDs were used to determine success of the matching where values <10 and close to 0 indicate a good match. 15, 17 We then assessed the association of a replacement ICD with survival in the matched data using conditional proportional hazard regression. 18 Additionally, we evaluated survival for both patients receiving new and replacement ICDs in the propensity-matched cohort when stratified according to device type (single chamber, dual chamber, or biventricular). This project was deemed exempt by the Institutional Review Boards at Beth Israel Deaconess Medical Center and the Hebrew SeniorLife Institute for Aging Research. 19 
Results
Baseline Characteristics
Among 533 817 procedures entered into the ICD Registry during the study period, 463 978 unique patients were eligible for these analyses (Figure 1 ). In this sample, 22.4% (n=103 985) of subjects received a replacement ICD, and 77.6% of subjects received a new ICD (n=359 993). Median follow-up times for the patients receiving replacement and new ICDs were 2.04 years (25%-75% IQR, 1.37-3.00) and 2.54 years (25%-75% IQR, 1.58-3.70), respectively.
Demographic, clinical, and procedural characteristics of the overall cohort and stratified by replacement versus new ICDs are presented in Table 1 . In unadjusted analyses, subjects receiving replacement versus new ICDs were significantly older (median age, 70.7 versus 67.5 years; SMD, 21.0%) and more frequently white (87.6% versus 81.5%; SMD, 15.3%). With respect to cardiac history, a greater proportion of subjects receiving replacement versus new ICDs had atrial fibrillation (41.8% versus 31.4%; SMD, 23.8%), ventricular tachycardia (60.5% versus 33.9%; SMD, 50.7%), sinus node dysfunction (31.7% versus 25.6%; SMD, 15.9%), and coronary artery bypass surgery (39.8% versus 33.3%; SMD, 14.4%). Subjects getting ICD replacement had relatively better functional status as measured NYHA classifications. Other comorbid conditions, including chronic obstructive lung disease, cerebrovascular disease, diabetes mellitus, and endstage renal disease, did not differ between the 2 groups.
In terms of baseline diagnostic studies, subjects who received replacement versus new ICDs had significantly higher LV ejection fractions (32.6% versus 27.7%; SMD, 25.3%), had wider QRS duration, and were more likely to have paced rhythms. Finally, with respect to the procedural details, the vast majority (92.8%) of replacement patients were admitted to the hospital for the implant procedure specifically, compared with only 60.8% of patients receiving initial ICDs (SMD, 57.5%). At the time of ICD replacement, 6540 (6.3%) of these patients also had an upgrade/lead addition, of which 4912 (75.2%) entailed upgrade to a biventricular system. Patients getting their ICDs replaced also more commonly received biventricular devices (43.1% versus 35.8%; SMD, 31.9%) and were more like to have secondary prevention of sudden death recorded as the indication for the procedure (34.9% versus 17.2%; SMD, 31.9%).
Adverse events during the index admission were relatively uncommon in both groups (Table 3) significantly more common among patients receiving new versus replacement ICDs (3.2% versus 0.9%; SMD, 10.3%). The most common complication after ICD replacement was a hematoma (0.4%), whereas lead dislodgement was the most common complication among those receiving new ICDs (1.0%).
The median time to replacement was only 4.6 years (25%-75% IQR, 3.7-5.8) for all replaced devices, 5.8 (25%-75% IQR, 4.2-7.5) for single-chamber, 5.1 (25%-75% IQR, 4.1-6.1) for dual-chamber, and 3.9 (25%-75% IQR, 3.2-4.6) years for biventricular devices (Figure 2 ).
Survival
The median survival of patients receiving replacement ICDs was 2.0 years (25%-75% IQR, 1.6-3.7) compared with 2.5 years (25%-75% IQR, 1.6-3.7) for those receiving new ICDs. Mortality at 1 year for those receiving replacement ICDs was 9.9% versus 9.4% after new ICD implantation. At 3 years, mortality for patients receiving replacement ICDs was 27.4% compared with 23.5% for those receiving new ICDs. The unadjusted HR comparing survival among patients getting replacement versus new ICDs was 1.18 (95% confidence interval, 1.16-1.19; P<0.0001; Figure 3 ). Propensity-score matching successfully paired 72 905 new and replacement patients ( Table 2 ). Survival after ICD replacement versus initial implant remained worse in the propensity match analysis (HR, 1.28; 95% confidence interval, 1.25-1.30; P<0.0001). HRs for survival for both patients receiving new and replacement ICDs stratified by device type are presented in Figure 4 . Overall, these illustrate differences in survival among these 3 groups, with greatest risk for death in patients with biventricular ICDs and a consistent hazard for patients after ICD replacement versus initial implant.
Discussion
To our knowledge, this is the largest and most complete description of patients receiving replacement ICDs and their outcomes, including long-term survival, and the most substantive direct comparison of patients receiving replacement and new ICDs. We found that patients receiving replacement ICDs are older and have a greater history of arrhythmias compared with those getting new devices. Although index admission complication rates were lower among patients undergoing device replacement, survival after procedure was worse. After propensity matching, patients receiving replacement ICDs remained at greater risk for death compared with patients receiving new ICDs (HR, 1.28; 95% confidence interval, 1.25-1.30; P<0.0001). In addition, we found that the mean battery life of new ICDs was <5 years, a duration much shorter than previously reported. 20, 21 Taken together, these data highlight differences in clinical features and outcomes for recipients of new and replacement ICDs, reinforce the disconnect between patient and device longevity, and provide the context for further prospective studies evaluating the clinical benefits of ICD replacement. Our results build on previous attempts to characterize the clinical course of patients after ICD implantation. Haines et al 2 used ICD Registry data from 2006 through 2008 with a focus only on index admission complications, including death. They reported an overall complication rate of 3.05% and developed a risk score that stratified this risk from <1.0% to ≥17%. They did not, however, report outcomes for routine ICD replacement specifically and did not characterize survival after the index admission. Poole et al 4 reported outcomes up to 6 months for 871 ICD replacements in the REPLACE Registry of both patients receiving ICDs and pacemaker, with the majority (96.7%) of procedures performed for battery depletion. In agreement with our data, they found only a <1% risk of periprocedural events (defined as <24 hours). However, extending their follow-up to 6 months identified a 4.0% risk of major and a 7.4% risk of minor complications, consistent with retrospective studies focusing on replacements performed for device malfunction and recalls. 22 20 reported a mean battery life of 5.5±0.1 years for a relatively large group of 1072 ICDs replaced because of battery depletion. Biventricular devices in this cohort (n=373) had a mean battery life of 4.7±0.1 years compared with our finding of a median of 3.90 and a mean of 3.92 for these ICDs. Therefore, our much larger study further strengthens advocacy to improve the longevity of these devices, particularly for patients receiving biventricular systems. 21 Cost-effectiveness analyses of ICDs have demonstrated exquisite sensitivity to battery life, with replacement after 3 years rather than 5 years increasing the cost per quality-adjusted life year by tens of thousands of dollars. 24 Similar analysis of cardiac resynchronization therapy are even more sensitive to battery life. 25 Our survival data for patients receiving replacement ICDs and direct comparison with patients receiving new ICDs further clarify the picture of postreplacement clinical experiences. Seminal clinical trials have described annual mortality rates of patients with ICDs ranging from 5% (in Sudden Cardiac Death in Heart Failure Trial [SCD-HeFT]) 26 to 8.5% Multicenter Automatic Defibrillator Implantation Trial -II (MADIT-II) 27 to 12% (Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure [COMPANION]), 28 with variable absolute reductions in mortality with devicebased therapy. Our study does not have a control group of patients without ICDs for comparison, and so we are unable to evaluate the mortality advantage ICD replacement provides compared with a nonreplacement strategy. Similarly, these data are not intended to identify a causal relationship between ICD replacement and an increased risk for death. Nevertheless, the comparatively higher mortality rate in the patients receiving replacement ICDs compared with patients receiving new ICDs, even after propensity matching for age and other covariates, suggests that directly extrapolating the benefits from these clinical trials to patients receiving replacement ICDs may not be straightforward. Again, our analysis does not compare ICD replacement with a nonreplacement strategy (either abandonment of the device or replacement of the ICD with a pacemaker generator) and, thus, cannot directly address the risks and benefits of replacement versus nonreplacement. 11 In addition, our results raise questions about what contributes to the excess hazard for patients receiving replacement ICDs.
Late complications, such as infections, were not captured by this database, and residual confounding from unmeasured variables (such as more precise estimations of heart failure severity) may in part explain these findings. Patients receiving ICD replacements are necessarily farther along their disease course, and this may influence their survival and susceptibility to sudden arrhythmic death in particular. Our determination of vital status does not include cause of death, so it remains uncertain whether the excess mortality arises from progression of cardiovascular disease or noncardiac causes, such as malignancies. It is of interest that despite having more arrhythmia, replacement ICD patients had, on average, higher left ventricular ejection fractions and less severe heart failure. This finding may indicate that these patients were sicker when their devices were initially placed and recovered, that the devices themselves may have contributed to clinical improvement, some selection bias existed on the part of operators avoiding replacements on specific patients, or selected survivor bias.
Our study results should be interpreted within the context of several potential limitations. Although our study population was largely white and male, the ICD Registry is representative of the population receiving ICDs in the United States. Our analytic approach contrasted patients receiving replacement ICDs and patients receiving new ICDs whose implants of interest occurred during the same time period, meaning that the initial implants for patients receiving replacement ICDs occurred ≈4 years earlier on average. Thus, it is possible that this difference in timing relative to publication of pivotal clinical trials and updated guidelines may have contributed in unmeasured ways to differences between the patient groups. For example, significantly more patients in the replacement ICD group were characterized as secondary prevention, but from these data, we cannot determine whether these patients were survivors of qualifying events before their first ICD procedure or whether these events occurred after an initial primary prevention device was placed. Finally, it is possible that some patients may have been eligible for ICD replacement during the study period but declined (because of comorbidity or for other reasons). However, this would tend to bias the replacement ICD group toward healthier patients, further strengthening the observation that survival after replacement is worse than after initial implantation.
In conclusion, the paucity of data on the features and clinical course of patients after ICD replacement poses significant challenges for developing clinical guidelines or promoting informed decision making surrounding these procedures. 11 Patients undergoing ICD replacement differ from those receiving initial ICD implants in several important ways and require new generators because of declining battery life more quickly than previously reported. After ICD replacement, patients are at an elevated risk for death compared with those receiving new ICDs. These estimates may provide context for patient and clinician expectations surrounding ICD implantation and replacement, but clinical trials are necessary to rigorously evaluate the clinical benefits of ICD replacement.
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